Actively Recruiting
Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation
Led by Regina Elena Cancer Institute · Updated on 2025-03-25
103
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study aims to validate the Decipher® genomic test, in which patients with biochemical recurrence after radical prostatectomy are treated with salvage radiotherapy with extreme hypofractionation (5+ Gy/fraction). Validating the Decipher® genomic classifier based on the expression of 22 RNA genes in the prospective study "esSBRT"
CONDITIONS
Official Title
Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients enrolled at IRE under the "esSBRT" protocol meeting its criteria
- Patients who have provided written informed consent personally or through a legal representative
You will not qualify if you...
- All exclusion criteria applied in the "esSBRT" study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCSS Regina Elena
Roma, Italy, 00144
Actively Recruiting
Research Team
G
Giuseppe Sanguineti, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here